NCA
UTHR icon

NCM Capital Advisers’s United Therapeutics UTHR Stock Holding History

NCM Capital Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$201K Sell
1,700
-132
-7% -$15.9K 0.6% 59
2016
Q2 		$194K Hold
1,832
– – 0.56% 59
2016
Q1 		$204K Hold
1,832
– – 0.59% 60
2015
Q4 		$287K Hold
1,832
– – 0.81% 56
2015
Q3 		$240K Buy
+1,832
New +$294K 0.71% 61

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM Capital Advisers's UTHR Position: Q3 2016 in Review

NCM Capital Advisers reduced its United Therapeutics (UTHR) stake by 7.2% in Q3 2016, selling an estimated $15.9K and leaving 1,700 shares worth $201K. The position accounts for 0.6% of the portfolio, ranked #59.

NCM Capital Advisers first reported a position in UTHR in Q3 2015 and has held it in 5 quarters since. The position peaked at $287K in Q4 2015. 394 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

  • NCM Capital Advisers held 1,700 shares of United Therapeutics worth $201K as of Q3 2016.
  • NCM Capital Advisers sold 132 United Therapeutics shares in Q3 2016, an estimated $15.9K.
  • United Therapeutics made up 0.6% of NCM Capital Advisers's portfolio in Q3 2016, its #59 holding.
  • NCM Capital Advisers first reported a position in United Therapeutics in Q3 2015 and has held it in 5 quarters since.
  • NCM Capital Advisers's United Therapeutics position peaked at $287K in Q4 2015.
  • 394 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on NCM Capital Advisers's 13F filing for Q3 2016, filed 7 Nov 2016.